Part II of the CTA dossier. Each Concerned Member State (CMS) evaluates Part II independently through its designated ethics committee(s).

The ethics committee provides an opinion on:

• Informed consent documents and process
• Insurance and indemnity arrangements
• Subject compensation
• Investigator qualifications and site suitability
• Recruitment and advertisement materials

These components are reviewed in parallel with the scientific assessment conducted by the Reporting Member State (RMS) under Part I.

Key Ethics Documents Required in Part II

Sponsors must ensure that the Part II submission includes:

• Final version of the Patient Information Sheet (PIS) and Informed Consent Form (ICF)
• Compensation details (financial, medical care)
• Insurance certificates covering the trial population
• CVs of principal investigators at each site
• Recruitment tools (posters, flyers, online ads)

Country-specific templates may apply — particularly for pediatric trials or vulnerable populations.

Sample Table: Ethics Committee Checklist for CTA Part II

Document	Mandatory?	Reviewed By
Informed Consent Form	Yes	National Ethics Committee
Insurance Certificate	Yes	Regulatory + Ethics Committee
Investigator CVs	Yes	National Ethics Committee
Recruitment Materials	Yes	Ethics Committee

Ethics Review Timelines, Multi-Country Considerations, and Best Practices

Review Timelines and Decision Phases

Ethics committee review follows a defined schedule under the CTR:

• Validation: 10 days to check completeness of submission
• Assessment: 45 days (in parallel with Part I review)
• Clock-stops: Initiated if questions are raised
• Decision Phase: Authorization or grounds for non-acceptance issued within 5 days after review

If deficiencies are found, the sponsor must respond within 12 days to continue the evaluation.

Decentralized Nature of Ethics Review

Unlike Part I of the CTA, which is assessed by one Reporting Member State (RMS), Part II is evaluated separately by each Concerned Member State. Therefore:

• Multiple ethics opinions are issued across participating countries
• Each national ethics body may have unique formatting or language preferences
• National legislation or cultural norms may influence the outcome

Sponsors must plan for these differences by tailoring documents and involving local affiliates or CROs familiar with national requirements.

Special Considerations: Vulnerable Populations and Data Protection

When the trial involves minors, pregnant women, or other vulnerable groups, the ethics committee will pay special attention to:

• Additional consent or assent procedures
• Safeguards for minimizing risk
• Compliance with GDPR and data subject rights

Sponsors should justify inclusion criteria, explain the direct benefit-to-risk ratio, and prepare layperson summaries where required.

Role of Insurance and Indemnity Review

Ethics committees verify that participants are protected in the event of injury or harm during the trial. Sponsors must provide:

• Insurance policies with coverage details
• Clear statements on liability for clinical negligence
• Proof of compliance with national minimum insurance thresholds

Missing or invalid documentation can lead to rejection of Part II even if the scientific components are acceptable.

Best Practices for Ethics Approval Success

To streamline the ethics review, sponsors should:

• Use harmonized ICF templates validated across EU sites
• Submit clean and redlined versions of revised documents
• Engage with ethics committees early, especially for complex protocols
• Maintain a centralized ethics documentation tracker

Consider submitting pre-submission queries to clarify expectations in challenging jurisdictions or high-risk therapeutic areas.

Conclusion: Ethics Committees as Gatekeepers of Participant Protection

Ethics committees play a vital role in clinical trial governance, particularly under the EU Clinical Trials Regulation. Their review ensures that trials uphold the highest ethical standards and that participant rights, safety, and privacy are respected throughout the study.

By integrating ethics considerations early, aligning documents across jurisdictions, and maintaining proactive communication with review bodies, sponsors can not only meet compliance requirements but also build trust and accountability into their clinical research programs.